Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
Edward Abraham(New York Medical College), Abla A. Creasey(California Institute for Regenerative Medicine), Charles L. Sprung(Hebrew University of Jerusalem), Steven M. Opal(Brown University), Antonio Artigas(Instituto de Salud Carlos III), Russell G. Postier, Sandra Percell(Novartis (Switzerland)), James C. Stolzenbach(Pfizer (United States)), Christian Zwingelstein(Novartis (Switzerland)), Christopher J. Doig(Alberta Health Services), Allan Seibert(Providence Park Hospital), Ignace Demeyer(Onze Lieve Vrouwziekenhuis Hospital), Petr Svoboda(Ministry of Health), Lona Poole(Novartis (Switzerland)), Jeffrey Tobias(Jazz Pharmaceuticals (United States)), Vincent Shu(Pfizer (United States)), Herbert Spapen(Universitair Ziekenhuis Brussel), C. Peckelsen(Memorial Hospital of Rhode Island), Konrad Reinhart(Humboldt-Universität zu Berlin), Angel López Rodríguez(Universidad Complutense de Madrid), Richard Beale(St Thomas' Hospital), C. De Deyne(Ziekenhuis Oost-Limburg), Pierre François Laterre(Université Paris-Sud), Judy Stone(Memorial), Stuart H. Simon, Bruce Light(St. Boniface Hospital), Ville Pettilä(University of Helsinki)
Cited by 958
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k